Premium
Treatment of Metastatic Chemodectoma
Author(s) -
Massey Vickie,
Wallner Kent
Publication year - 1992
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19920201)69:3<790::aid-cncr2820690329>3.0.co;2-u
Subject(s) - medicine , chemodectoma , radiation therapy , surgery , metastatic carcinoma , ommaya reservoir , spinal cord compression , cyclophosphamide , chemotherapy , dacarbazine , vincristine , cancer , radiology , carcinoma , spinal cord , paraganglioma , psychiatry
Six patients were treated for metastatic chemodectoma at Memorial Sloan‐Kettering Cancer Center from 1971 through 1988. Four patients' primary tumors arose in the cervical region, and two arose in the retroperitoneum. Four patients received a total of eight different chemotherapeutic regimens, including cisplatin, doxorubicin, cyclophosphamide, and dacarbazine. Metastatic sites treated included bone, liver, lung, and retroperitoneum. No patient had a response to chemotherapy. Four patients received a total of nine courses of radiation therapy for palliation of bone metastases. Pain relief was complete in eight patients and partial in one. One patient was irradiated for a mass in the left psoas muscle, with stabilization of disease for 6 months after treatment. One patient was irradiated for epidural compression at T 6 , with resolution of neurologic symptoms and 50% clearing of the spinal block on follow‐up myelogram. Recurrence or progression of disease in a previously irradiated site occurred in one patient 2 years after treatment. One patient was lost to follow‐up 3 months after radiation therapy for epidural compression. The other five patients died of widespread metastatic disease 6 months to 9 years after initial treatment for their metastatic disease.